What development phase is Pexion in?

Pexion is FDA-approved (marketed).

What is the generic name of Pexion?

imepitoin is the generic (nonproprietary) name of Pexion.

Last reviewed 2026-04-20 · How we verify

Pexion (imepitoin)

FDA-approved active Quality 0/100

Pexion (imepitoin) is a small molecule developed by Dechra Pharmaceuticals, currently owned by the same company. It is used to treat canine epilepsy. The exact mechanism of action is not fully understood, but it is believed to modulate the activity of certain neurotransmitters in the brain. Pexion is a patented medication, and its commercial status is not yet off-patent. Key safety considerations include potential side effects such as vomiting and diarrhea.

At a glance

Generic name	imepitoin
Therapeutic area	Neuroscience
Phase	FDA-approved

Approved indications

No approved indications tracked.

Common side effects

No common side effects on file.

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:

Pexion CI brief — competitive landscape report
Pexion updates RSS · CI watch RSS
portfolio CI